BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 30, 2010
 |  BioCentury  |  Product Development

Roche Goes Shopping for Staples

Roche increases commitment to Stapled Peptides technology at Aileron Therapeutics

Targeting intracellular protein-protein interactions is difficult because small molecules lack sufficient specificity, while molecules with higher specificity such as antibodies are too big to enter the cell. Aileron Therapeutics Inc. says its Stapled Peptide technology creates cell-penetrating peptides that provide antibody-like specificity.

A year after Roche's venture arm invested in the biotech's series D round, the pharma has placed a second bet on the technology in a collaboration to develop and market Stapled Peptide therapeutics.

Aileron and Roche now will discover, develop and commercialize Stapled Peptide therapeutics against up to five undisclosed targets for cancer, virology, inflammation, metabolism and neurology. Aileron will receive $25 million in technology access fees and R&D support.

The companies declined to break out how much of the money will go to FTEs, but Aileron will be responsible for the majority of discovery and preclinical development. Roche will have primary responsibility for further development and commercialization.

Aileron is eligible for up to $1.1 billion in milestones if products...

Read the full 804 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >